Edwards Lifesciences Corp reports $1.72 billion revenue for quarter ended September 30, 2026, up 10.5%

ยท EW

Edwards Lifesciences Corp reported revenue of $1.72 billion for the quarter ended September 30, 2026, an increase of 10.5% from the same quarter a year earlier ($1.55 billion).

For the same period it posted net income of $307.5 million, up 5.6%, or $0.53 per diluted share (0.50 a year earlier).

That is a net margin of 17.9%.

On Sanad's AAOIFI Standard 21 screen, Edwards Lifesciences Corp is currently compliant: interest-bearing debt is 1% of market capitalisation (limit 30%), and impure income is 2.8% of revenue (limit 5%).

Source: 10-Q filed with the U.S. Securities and Exchange Commission on November 4, 2026. View the filing. Figures are as reported in the filing. This is information, not investment advice.

More Edwards Lifesciences Corp news